Bioventus Inc.
Bioventus Inc. (BVS): 6 pipeline candidates · ~4 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
3.7 months
D/E 2.20
Lead: Approved
6 candidates
N/A
0 buys · 1 sell (180d)
A transparent, data-derived signal for Bioventus Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$577.9M
Cash
$35.8M
Quarterly Burn
$80.8M
Runway
3.7 mo
Revenue
$132.1M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (6 candidates)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
155
Total value held
$357.5M
| Holder | Shares | Value |
|---|---|---|
| essex woodlands management, inc. | 13,021,324 | $118.9M |
| vanguard capital management llc | 3,429,414 | $31.3M |
| blackrock, inc. | 3,133,541 | $28.6M |
| royce & associates lp | 1,541,282 | $14.1M |
| geode capital management, llc | 1,168,247 | $10.7M |
| state street corp | 988,367 | $9.0M |
| vanguard portfolio management llc | 973,004 | $8.9M |
| dimensional fund advisors lp | 873,138 | $8.0M |
| hillsdale investment management inc. | 671,139 | $6.1M |
| oberweis asset management inc/ | 628,114 | $5.7M |
Showing top 10 of 155 institutional holders of Bioventus Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Bioventus Inc.'s pipeline?
Bioventus Inc. (BVS) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Bioventus Inc.'s lead drug candidate?
Bioventus Inc.'s most advanced tracked candidate is assets (Approved).
What is Bioventus Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Bioventus Inc. has approximately 3.7 months of cash runway.
What is Bioventus Inc.'s market capitalization?
Bioventus Inc.'s market capitalization is approximately $577.9M.
Who is the CEO of Bioventus Inc.?
Mr. Robert E. Claypoole is the chief executive officer of Bioventus Inc. (BVS).
Get the full picture on Bioventus Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.